The immediate effects and long-term harms of menopause for women are of increasing concern. Hormone supplementation therapy (HRT) is an important part of the strategy to maintain the health of postmenopausal women and remains the most effective measure, especially for vasodilatory symptoms and genitourinary tract problems. By grasping the principles of hormone supplementation therapy and initiating it early (<10 years after menopause and before age 60), the maximum benefit of hormone supplementation therapy can be realized. The relationship between hormone therapy and breast cancer is still inconclusive, and the use of any drug within 5 years does not increase breast cancer. The advent of newer generation progestins, such as drospirenone, with its anti-salt corticosteroid effect minimizes the adverse effects of traditional progestins and may provide additional benefits to patients. Goals of hormone supplementation for menopausal women Improve menopausal symptoms such as hot flashes and sweats, depression and anxiety, improve genitourinary tract atrophy, prevent osteoporosis, improve quality of life, and prevent and delay chronic diseases of aging (cardiovascular disease, Alzheimer's disease). The latest recommendations of the International Menopause Society (IMS) on postmenopausal hormone therapy (2011): Hormone supplementation is an important part of the strategy to maintain the health of postmenopausal women, hormone therapy remains the most effective treatment for vasodilatory symptoms and genitourinary tract problems due to hormone deficiency, and individualized hormone therapy can improve sexual function and quality of life. Before the age of 60: HRT is a reasonable first-line treatment to prevent bone loss; after the age of 60: whether to apply HRT when the sole purpose is to prevent fracture should be determined on an individual basis. Follow-up management of hormone supplementation Assess changes in indications, contraindications and cautions after one year of treatment. Physical examination: blood pressure, weight, height, breast and gynecological examinations; ancillary examinations: pelvic ultrasound, breast ultrasound or mammogram, lipid and liver function, bone density measurement can be done once every 2-3 years. Choice of hormone supplementation treatment plan 1. Declining progesterone level in early perimenopause: progesterone alone. 2. Hysterectomy without endometrial protection: estrogen alone such as estradiol valerate tablets (Glivec) 1 to 2 mg/d, continuous or intermittent application. 3.With uterus/perimenopause/to be menstruated: estrogen and progestin cycle treatment such as Clomid: each tablet contains estradiol valerate 2mg, 21 tablets in total, the last 10 tablets contain cyproterone acetate 1mg; Fentanyl: each tablet contains 17b estradiol 1mg, 28 tablets in total, the last 14 tablets contain dydrogesterone 10mg; Tocopherol 1~2mg/d, 21~28 days in a row, followed by dydrogesterone 10~14 days 10-20mg/day, or 200mg/day of micronized progesterone. 4. With uterus/post-menopause/don't want to menstruate: continuous combined treatment with estrogen and progestin such as Anjingyi: each tablet contains 17b estradiol 1mg and drospirenone 2mg; tibolone 1.25mg/day; tegretol 1~2mg/day, together with dydrogesterone 5mg/day or micronized progesterone 50~100mg/day.